Aimée R. Kreimer
#141,851
Most Influential Person Now
American cancer epidemiologist
Aimée R. Kreimer's AcademicInfluence.com Rankings
Aimée R. Kreimermedical Degrees
Medical
#3736
World Rank
#4242
Historical Rank
#563
USA Rank
Epidemiology
#794
World Rank
#829
Historical Rank
#117
USA Rank
Download Badge
Medical
Aimée R. Kreimer's Degrees
- Bachelors Biology University of California, Berkeley
- PhD Epidemiology Johns Hopkins University
Similar Degrees You Can Earn
Why Is Aimée R. Kreimer Influential?
(Suggest an Edit or Addition)According to Wikipedia, Aimée Rebecca Kreimer is an American cancer epidemiologist who researches the etiology and prevention of human papillomavirus infection and cancer prevention. She is a senior investigator in the infections and immunoepidemiology branch at the National Cancer Institute.
Aimée R. Kreimer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Case-control study of human papillomavirus and oropharyngeal cancer. (2007) (2569)
- Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review (2005) (2126)
- Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica (2013) (412)
- Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. (2004) (393)
- Oral Human Papillomavirus in Healthy Individuals: A Systematic Review of the Literature (2010) (293)
- Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. (2013) (285)
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine (2011) (259)
- Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. (2015) (252)
- EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus‐related cancer incidence by gender and anatomic site of infection (2015) (251)
- Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study (2013) (239)
- Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial (2009) (207)
- Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial (2013) (200)
- The Epidemiology of Oral HPV Infection among a Multinational Sample of Healthy Men (2010) (193)
- HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis (2017) (183)
- Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. (2011) (178)
- Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort (2009) (159)
- Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. (2011) (153)
- Risk Prediction for Breast, Endometrial, and Ovarian Cancer in White Women Aged 50 y or Older: Derivation and Validation from Population-Based Cohort Studies (2013) (137)
- Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening (2009) (129)
- Anal Cancer Incidence in the United States, 1977–2011: Distinct Patterns by Histology and Behavior (2015) (118)
- Associations of Oral α-, β-, and γ-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. (2016) (115)
- Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study. (2016) (113)
- Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. (2012) (111)
- Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment (2016) (109)
- Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies (2018) (97)
- Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. (2016) (94)
- Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. (2016) (93)
- Human Papillomavirus Testing Following Loop Electrosurgical Excision Procedure Identifies Women at Risk for Posttreatment Cervical Intraepithelial Neoplasia Grade 2 or 3 Disease (2006) (89)
- No role for human papillomavirus in esophageal squamous cell carcinoma in China (2010) (80)
- Gender Differences in Sexual Biomarkers and Behaviors Associated With Human Papillomavirus-16, −18, and −33 Seroprevalence (2004) (79)
- HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas (2005) (73)
- Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer (2017) (71)
- Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial (2018) (68)
- Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus–driven oropharyngeal cancer and are associated with recurrence (2017) (65)
- Diet and body mass, and oral and oropharyngeal squamous cell carcinomas: Analysis from the IARC multinational case–control study (2006) (63)
- Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. (2019) (62)
- Combined effects of smoking and HPV16 in oropharyngeal cancer. (2016) (61)
- Evaluation of durability of a single-dose of the bivalent HPV vaccine: the CVT Trial. (2020) (54)
- Prospects for prevention of HPV-driven oropharynx cancer. (2014) (54)
- Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. (2015) (53)
- Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis (2015) (50)
- Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study (2015) (49)
- Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. (2019) (46)
- Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica. (2013) (46)
- HPV-associated Oropharyngeal Cancers—Are They Preventable? (2011) (46)
- Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica. (2012) (45)
- Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium (2019) (41)
- The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. (2015) (41)
- Screening for human papillomavirus‐driven oropharyngeal cancer: Considerations for feasibility and strategies for research (2018) (39)
- Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials (2017) (38)
- Viral Determinants of Human Papillomavirus Persistence following Loop Electrical Excision Procedure Treatment for Cervical Intraepithelial Neoplasia Grade 2 or 3 (2007) (37)
- Long‐term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment (2012) (37)
- Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. (2020) (36)
- Anthropometry and head and neck cancer:a pooled analysis of cohort data. (2015) (32)
- Characterization of human papillomavirus antibodies in individuals with head and neck cancer. (2016) (31)
- Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial (2015) (31)
- Oral Cancer Knowledge: A Survey Administered to Patients in Dental Departments at Large Italian Hospitals (2011) (29)
- Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: the CVT Trial. (2020) (29)
- Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing. (2014) (27)
- Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. (2020) (25)
- Epidemiologic analysis of histologic cervical inflammation: relationship to human papillomavirus infections. (2008) (24)
- Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines (2016) (23)
- Evaluation of the FTA Carrier Device for Human Papillomavirus Testing in Developing Countries (2012) (19)
- Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants. (2007) (19)
- An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study (2018) (18)
- Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. (2014) (18)
- Lessons from Australia: Human Papillomavirus Is Not a Major Risk Factor for Esophageal Squamous Cell Carcinoma (2010) (16)
- Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. (2015) (16)
- Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes (2019) (15)
- Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials (2018) (15)
- Efficacy of the AS04-adjuvanted HPV-16/18 vaccine: Pooled analysis of the Costa Rica Vaccine and PATRICIA randomized controlled trials. (2019) (15)
- Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes (2019) (15)
- Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. (2014) (14)
- Self-Reported Oral Hygiene Habits among Dental Patients in Italy (2012) (14)
- The Gastric Cardia Is Not a Target for Human Papillomavirus–Induced Carcinogenesis (2010) (12)
- Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. (2018) (11)
- HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection (2016) (10)
- Oral sexual behaviors and the prevalence of oral human papillomavirus infection. (2009) (10)
- The Natural History of Oral Human Papillomavirus in Young Costa Rican Women (2017) (10)
- Trends in cervical cancer incidence in younger US women from 2000 to 2013. (2017) (10)
- HPV vaccination initiation after the routine-recommended ages of 11–12 in the United States (2015) (10)
- Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections. (2009) (9)
- Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. (2011) (9)
- HPV vaccination initiation after the routine-recommended ages of 11-12 in the United States. (2016) (9)
- The beginning of the end: vaccine prevention of HPV-driven cancers. (2015) (8)
- Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial (2022) (8)
- Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. (2020) (7)
- Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium (2022) (5)
- Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial (2021) (5)
- Number of human papillomavirus vaccine doses and condyloma. (2014) (5)
- Different human papillomavirus types share early natural history transitions in immunocompetent women (2022) (4)
- Review of the current published evidence on single-dose HPV vaccination 2nd Edition (2019) (4)
- Risk Factors for NON-HPV16/18 Cervical Infections and Associated Lesions Among HPV-DNA-Negative Women Vaccinated Against HPV16/18 in the Costa Rica Vaccine Trial (CVT). (2020) (3)
- Reply to P.E. Castle. (2014) (3)
- Prioritisation of the human papillomavirus vaccine in a time of constrained supply. (2020) (3)
- Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials. (2020) (3)
- Risk Factors for NON-HPV16/18 Cervical Infections and Associated Lesions Among HPV-DNA-Negative Women Vaccinated Against HPV16/18 in the Costa Rica Vaccine Trial (CVT). (2020) (3)
- Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs. (2022) (2)
- The Epidemiology and Control of Human Papillomavirus Infection and Clinical Disease (2013) (2)
- Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. (2022) (2)
- Cumulative false-positives (FP) in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial (2007) (2)
- Association between Common Vaginal Infections and Cervical Non-HPV16/18 Infection in HPV-Vaccinated Women. (2020) (2)
- Effect of HPV on cervical cancer screening in Alberta (2016) (1)
- Real-World HPV Vaccine Effectiveness Studies: Guideposts for Interpretation of Current and Future Studies. (2021) (1)
- Abstract 4680: Efficacy of the HPV16/18 vaccine against cervical, anal, and oral HPV infection among women with and without previous HPV16/18 exposure (2015) (1)
- Abstract 3625: An analysis of human papilloma virus (HPV) E6 antibodies and risk of head and neck cancer: two large European studies. (2013) (1)
- Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis. (2022) (1)
- Performance of cervical screening a decade following HPV vaccination: The Costa Rica Vaccine Trial. (2022) (1)
- HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial (2022) (1)
- Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial (2022) (0)
- molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history (2022) (0)
- Abstract B008: Autoimmune disease and the risk of anal cancer in the U.S. elderly population (2023) (0)
- Trends in incidence rates of head and neck squamous cell carcinomas overall and by potential relatedness to human papillomavirus, Costa Rica 2006 to 2015 (2023) (0)
- HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial (2022) (0)
- Estimating human papillomavirus vaccine efficacy from a single-arm trial: Proof-of-principle in the Costa Rica Vaccine Trial. (2023) (0)
- Fewer than three doses of HPV vaccine - Authors' reply. (2015) (0)
- Public health opportunities resulting from sufficient HPV vaccine supply and a single-dose vaccination schedule. (2022) (0)
- Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study (2020) (0)
- The impact of the HIV epidemic on U.S. anal cancer rates, 1980-2007 (2012) (0)
- Abstract LB-181: Oral HPV DNA detection and subsequent risk of head and neck cancers in two prospective cohorts (2015) (0)
- impact of the H iV epidemic on the incidence r ates of Anal c ancer in the United States (2012) (0)
- HPV-Associated Cancer Incidence by Disaggregated Asian American, Native Hawaiian, and Other Pacific Islander Ethnicity. (2023) (0)
- Comparison of Immune Responses after One Dose of HPV Vaccine in a Dose-Reduction HPV Vaccine Trial in Adolescent Girls in Tanzania to the Costa Rica Vaccine and India HPV Vaccine Trials (2022) (0)
- The impact of the HIV epidemic on U.S. anal cancer rates, 1980-2007 (2012) (0)
- Reproducible And Clinically Translatable Deep Neural Networks For Cervical Screening (2022) (0)
- sons from Australia: Human Papillomavirus Is Not a Major (2010) (0)
- Commentary sons from Australia : Human Papillomavirus Is Not a Major B & P Factor for Esophageal Squamous Cell Carcinoma (2010) (0)
- REPRODUCIBLE AND CLINICALLY TRANSLATABLE DEEP NEURAL NETWORKS FOR CANCER SCREENING (2023) (0)
- HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial (2022) (0)
- Fewer than three doses of HPV vaccine - reply (2015) (0)
This paper list is powered by the following services:
Other Resources About Aimée R. Kreimer
What Schools Are Affiliated With Aimée R. Kreimer?
Aimée R. Kreimer is affiliated with the following schools:
